| Bioactivity | Azemiglitazone (MSDC-0602), a PPARγ-sparing thiazolidinedione (TZD), interacts with the mitochondrial pyruvate carrier (MPC) and inhibits its activity and has the potential for type 2 diabetes study with reducing risk of PPARγ-mediated side effects[1][2]. | ||||||||||||
| Name | Azemiglitazone | ||||||||||||
| CAS | 1133819-87-0 | ||||||||||||
| Formula | C19H17NO5S | ||||||||||||
| Molar Mass | 371.41 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Chen Z, et al. Resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J Biol Chem. 2012 Jul 6;287(28):23537-48. [2]. Vigueira PA, et al. The beneficial metabolic effects of sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism. Exp Physiol. 2017 Aug 1;102(8):985-999. |
Azemiglitazone
CAS: 1133819-87-0 F: C19H17NO5S W: 371.41
Azemiglitazone (MSDC-0602), a PPARγ-sparing thiazolidinedione (TZD), interacts with the mitochondrial pyruvate carrier
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.